Key clinical point: More women with early breast cancer and a high risk for distant recurrence remained recurrence free after chemotherapy plus endocrine therapy, compared with endocrine therapy alone.
Major finding: The estimated rate of freedom from recurrent breast cancer at a distant site was 93% at 5 years.
Study details: The data come from a secondary analysis of 1,389 women from the multicenter, randomized TAILORx trial.
Disclosures: The study was supported in part by the National Cancer Institute, the Canadian Cancer Society Research Institute, the Breast Cancer Research Foundation, the Komen Foundation, and the Breast Cancer Research Stamp issued by the United States Postal Service. Dr. Sparano disclosed receiving grants from the National Cancer Institute during the study. Of the remaining authors, several disclosed receiving personal or speaker fees from the assay manufacturer, Genomic Health; one author received funding from the company during the study.
Sparano J et al. JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794.